Common mutations and polymorphisms predicting adverse cardiovascular events: current view

Author： Visvikis-Siest Sophie   Stathopoulou Maria G   Ndiaye Ndeye Coumba  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.13, Iss.16, 2012-12, pp. : 1875-1878

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Verapamil for preventing adverse cardiovascular events

By  

Inpharma, Vol. 1, Iss. 1385, 2003-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Ephedra: risk of adverse cardiovascular events

By  

Inpharma, Vol. 1, Iss. 1325, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Lipid Management Strategies for the Prevention of Adverse Cardiovascular Events

By  

Heart Drug, Vol. 2, Iss. 4, 2002-11 ,pp. : 159-161

Karger

Access to resources Recommend Favorite

Thiazolidinedione treatment is not associated with an increased risk of major adverse cardiovascular events

By  

Inpharma, Vol. 1, Iss. 1643, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Cardiovascular Events Associated With Different Combined Oral Contraceptives: A Review Of Current Data

By Hannaford P.  

Drug Safety, Vol. 22, Iss. 5, 2000-05 ,pp. : 361-371

Adis International

Access to resources Recommend Favorite